- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Alnylam Pharmaceuticals received regulatory approval for its lead drug in both the US and Europe.
2 reports, 1 independent
Updated Jul 2
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Alnylam Pharmaceuticals received regulatory approval for its lead drug in both the US and Europe.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
-
Alnylam Pharmaceuticals
biopharmaceutical company
Nothing else this week.
- FDA
Related events
- Both the FDA and the European Medicines Agency govern drug approval processes.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- Both the FDA and European Medicines Agency must adopt evidence-based principles for drug regulation.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.
Coverage
Newest first; wire copies grouped- BarchartProfits May Be Just Around the Corner for This Strong-Buy Pharma Stock Alnylam Pharmaceuticals (ALNY) shows strong price momentum, hitting new all-time highs on Aug. 11. ALNY has a 100% technical “Bu